Shares of Gilead Sciences (GILD) gained 3.25% to close the trading session on Aug 15 at $99.45 per share following the favorable verdict by an arbitration panel in a patent infringement case with Roche (RHHBY). The tussle was regarding Gilead’s blockbuster hepatitis C drug, Sovaldi (sofosbuvir). Gilead received further encouraging news on Sovaldi when U.K.’s…
Media reports over the weekend suggested Valeant Pharmaceuticals VRX held merger discussions with Actavis ACT , which may now have stalled on financial considerations. Valeant had been signaling that it was seeking to pursue a large acquisition or a merger of equals, so the magnitude of the deal was not surprising, but we were a…
The trading session has ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P…
A benign catastrophe season and continued improvement in underwriting margins at majority-owned OneBeacon OB led to a 3% sequential increase in adjusted book value to $606 per share at White Mountains Insurance Group WTM . In comparison with last year’s first quarter, the combined ratio (expense divided by earned premiums) fell to 81% from 84%…
Shares of MannKind Corp. have been on a wild ride over the past year. Most of this volatility is the result of emotionally-charged retail investors pushing the stock past realistic valuation levels. This stock serves as another glaring example as to why it’s generally a bad idea to follow the crowd when investing in biotech…
Wynn Resorts WYNN reported weak first-quarter results, as the company continued to perform poorly in Macau due to intensifying competition from new casinos on the Cotai Strip. Revenue and EBITDA were above consensus estimates, but only because the company had an unusually high hold rate for VIP table games in Macau and table games in…
